SAB Biotherapeutics company info

What does SAB Biotherapeutics do?
SAB Biotherapeutics (NASDAQ: SABS) pioneers groundbreaking biotechnology solutions with a focus on human antibodies. Their proprietary SAB CAP Technology™ enables the development of fully human polyclonal antibodies without human donors, promising breakthroughs in treating infectious diseases, autoimmune disorders, and cancer. The company's clinical-stage initiatives, such as human anti-thymocyte immunoglobulin (hIgG) for type 1 diabetes, underscore their commitment to advancing healthcare. With a robust immunotherapy platform and a dedication to innovation, SAB Biotherapeutics stands poised to reshape medical treatments and address critical global health challenges, offering hope for improved patient outcomes worldwide.
SAB Biotherapeutics company media
Company Snapshot

Is SAB Biotherapeutics a public or private company?

key
Ownership
Public

How many people does SAB Biotherapeutics employ?

people
Employees
57

What sector is SAB Biotherapeutics in?

pie chart
Sector
Health Care

Where is the head office for SAB Biotherapeutics?

location pin
Head Office
Sioux Falls, United States

What year was SAB Biotherapeutics founded?

founded flag
Year Founded
2014
What does SAB Biotherapeutics specialise in?
/Antibody Therapies /COVID-19 Treatment /Immunotherapies Production /Influenza Therapeutics /Disease Research /Drug Development

What are the products and/or services of SAB Biotherapeutics?

Overview of SAB Biotherapeutics offerings
Fully Human Polyclonal Antibodies: SAB Biotherapeutics specializes in the development of fully human polyclonal antibodies using their innovative technology platform.
Immunotherapy Platform: The company offers a cutting-edge immunotherapy platform for the development of novel therapeutic solutions targeting various diseases, including infectious diseases, autoimmune disorders, and cancer.
Clinical-Stage Therapeutics: SAB Biotherapeutics may have clinical-stage therapeutic candidates targeting specific diseases or medical conditions, such as type 1 diabetes (T1D), utilizing their human anti-thymocyte immunoglobulin (hIgG).
Research and Development Services: SAB Biotherapeutics might offer research and development services, including collaboration opportunities with pharmaceutical companies, academic institutions, and research organizations.
Antibody Production Technologies: The company could provide technologies and expertise related to antibody production, purification, and characterization, leveraging their proprietary methods for scalable and cost-effective manufacturing.
Biotechnology Solutions: SAB Biotherapeutics likely offers a range of biotechnology solutions aimed at advancing medical research, drug discovery, and therapeutic development, with a focus on improving patient outcomes and addressing unmet medical needs.

Who is in the executive team of SAB Biotherapeutics?

SAB Biotherapeutics leadership team
  • Mr. Samuel J. Reich
    Mr. Samuel J. Reich
    CEO & Executive Chairman
  • Dr. Eddie Joe Sullivan Ph.D.
    Dr. Eddie Joe Sullivan Ph.D.
    Co-Founder, President & Director
  • Ms. Christine E. Hamilton M.B.A.
    Ms. Christine E. Hamilton M.B.A.
    Co-Founder & Independent Director
  • Mr. Michael George King Jr.
    Mr. Michael George King Jr.
    EVP & CFO
  • Dr. Christoph  Bausch M.B.A., Ph.D.
    Dr. Christoph Bausch M.B.A., Ph.D.
    Executive VP & COO
  • Dr. Alexandra  Kropotova M.B.A., M.D.
    Dr. Alexandra Kropotova M.B.A., M.D.
    Executive VP & Chief Medical Officer
  • Dr. Edward D. Hamilton D.V.M.
    Dr. Edward D. Hamilton D.V.M.
    Co-Founder & Board Observer
  • Dr. Carlos N. Carillo Ph.D.
    Dr. Carlos N. Carillo Ph.D.
    Senior Vice President of Regulatory Affairs